THYSSENKRUPP NUCERA AG & CO (NCH2.DE) Fundamental Analysis & Valuation

FRA:NCH2 • DE000NCA0001

8.48 EUR
-0.12 (-1.4%)
Last: Mar 6, 2026, 05:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This NCH2.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall NCH2 gets a fundamental rating of 3 out of 10. We evaluated NCH2 against 43 industry peers in the Construction & Engineering industry. The financial health of NCH2 is average, but there are quite some concerns on its profitability. NCH2 is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. NCH2.DE Profitability Analysis

1.1 Basic Checks

  • In the past year NCH2 has reported negative net income.
  • In the past year NCH2 had a positive cash flow from operations.
  • NCH2 had positive earnings in each of the past 5 years.
  • In multiple years NCH2 reported negative operating cash flow during the last 5 years.
NCH2.DE Yearly Net Income VS EBIT VS OCF VS FCFNCH2.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • NCH2 has a worse Return On Assets (-0.65%) than 86.05% of its industry peers.
  • NCH2 has a Return On Equity of -0.99%. This is amonst the worse of the industry: NCH2 underperforms 86.05% of its industry peers.
Industry RankSector Rank
ROA -0.65%
ROE -0.99%
ROIC N/A
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
NCH2.DE Yearly ROA, ROE, ROICNCH2.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 2 4 6 8 10

1.3 Margins

  • In the last couple of years the Profit Margin of NCH2 has declined.
  • NCH2 has a worse Gross Margin (14.56%) than 76.74% of its industry peers.
  • NCH2's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NCH2 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
NCH2.DE Yearly Profit, Operating, Gross MarginsNCH2.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NCH2.DE Health Analysis

2.1 Basic Checks

  • NCH2 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NCH2 remains at a similar level compared to 1 year ago.
  • NCH2 has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NCH2 has a worse debt to assets ratio.
NCH2.DE Yearly Shares OutstandingNCH2.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NCH2.DE Yearly Total Debt VS Total AssetsNCH2.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 3.13 indicates that NCH2 is not in any danger for bankruptcy at the moment.
  • NCH2 has a better Altman-Z score (3.13) than 90.70% of its industry peers.
  • NCH2 has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • With an excellent Debt to Equity ratio value of 0.03, NCH2 belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 3.13
ROIC/WACCN/A
WACC7.4%
NCH2.DE Yearly LT Debt VS Equity VS FCFNCH2.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • NCH2 has a Current Ratio of 2.80. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.80, NCH2 belongs to the top of the industry, outperforming 97.67% of the companies in the same industry.
  • A Quick Ratio of 2.31 indicates that NCH2 has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 2.31, NCH2 belongs to the best of the industry, outperforming 97.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.31
NCH2.DE Yearly Current Assets VS Current LiabilitesNCH2.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NCH2.DE Growth Analysis

3.1 Past

  • The earnings per share for NCH2 have decreased strongly by -142.86% in the last year.
  • The earnings per share for NCH2 have been decreasing by -26.62% on average. This is quite bad
  • Looking at the last year, NCH2 shows a very negative growth in Revenue. The Revenue has decreased by -20.37% in the last year.
  • NCH2 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 27.16% yearly.
EPS 1Y (TTM)-142.86%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-128.57%
Revenue 1Y (TTM)-20.37%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-43.89%

3.2 Future

  • Based on estimates for the next years, NCH2 will show a very strong growth in Earnings Per Share. The EPS will grow by 109.64% on average per year.
  • Based on estimates for the next years, NCH2 will show a quite strong growth in Revenue. The Revenue will grow by 15.35% on average per year.
EPS Next Y-38.12%
EPS Next 2Y109.02%
EPS Next 3Y97.73%
EPS Next 5Y109.64%
Revenue Next Year-33.39%
Revenue Next 2Y-9.55%
Revenue Next 3Y-0.45%
Revenue Next 5Y15.35%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NCH2.DE Yearly Revenue VS EstimatesNCH2.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NCH2.DE Yearly EPS VS EstimatesNCH2.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. NCH2.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NCH2. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 64.70 indicates a quite expensive valuation of NCH2.
  • 79.07% of the companies in the same industry are cheaper than NCH2, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.79. NCH2 is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 64.7
NCH2.DE Price Earnings VS Forward Price EarningsNCH2.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • 76.74% of the companies in the same industry are cheaper than NCH2, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 113.23
NCH2.DE Per share dataNCH2.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NCH2's earnings are expected to grow with 97.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y109.02%
EPS Next 3Y97.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NCH2.DE Dividend Analysis

5.1 Amount

  • No dividends for NCH2!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NCH2.DE Fundamentals: All Metrics, Ratios and Statistics

THYSSENKRUPP NUCERA AG & CO

FRA:NCH2 (3/6/2026, 5:26:51 PM)

8.48

-0.12 (-1.4%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)02-11
Earnings (Next)05-12
Inst Owners11.34%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.07B
Revenue(TTM)729.20M
Net Income(TTM)-7.40M
Analysts76.67
Price Target11.25 (32.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-296.08%
Min EPS beat(2)-492.16%
Max EPS beat(2)-100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.68%
Min Revenue beat(2)-12.74%
Max Revenue beat(2)-2.62%
Revenue beat(4)0
Avg Revenue beat(4)-8.39%
Min Revenue beat(4)-12.74%
Max Revenue beat(4)-2.62%
Revenue beat(8)1
Avg Revenue beat(8)-4.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.35%
PT rev (3m)-7.7%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-88.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.12%
Revenue NY rev (3m)-22.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 64.7
P/S 1.47
P/FCF N/A
P/OCF 66.53
P/B 1.43
P/tB 1.62
EV/EBITDA 113.23
EPS(TTM)-0.06
EYN/A
EPS(NY)0.13
Fwd EY1.55%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.13
OCFY1.5%
SpS5.77
BVpS5.92
TBVpS5.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.65%
ROE -0.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.56%
FCFM N/A
ROA(3y)1.12%
ROA(5y)1.92%
ROE(3y)1.76%
ROE(5y)3.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-29.84%
PM growth 5Y-42.32%
GM growth 3Y-10.67%
GM growth 5Y-10.96%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 6.58
Cap/Depr 295.49%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion 423.68%
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.31
Altman-Z 3.13
F-Score4
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)192.94%
Cap/Depr(5y)124.39%
Cap/Sales(3y)2.25%
Cap/Sales(5y)1.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-142.86%
EPS 3Y-8.6%
EPS 5Y-26.62%
EPS Q2Q%-128.57%
EPS Next Y-38.12%
EPS Next 2Y109.02%
EPS Next 3Y97.73%
EPS Next 5Y109.64%
Revenue 1Y (TTM)-20.37%
Revenue growth 3Y30.18%
Revenue growth 5Y27.16%
Sales Q2Q%-43.89%
Revenue Next Year-33.39%
Revenue Next 2Y-9.55%
Revenue Next 3Y-0.45%
Revenue Next 5Y15.35%
EBIT growth 1Y-86.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year562.17%
EBIT Next 3Y202.31%
EBIT Next 5Y111.63%
FCF growth 1Y114.4%
FCF growth 3Y-49.91%
FCF growth 5Y34.5%
OCF growth 1Y180.81%
OCF growth 3Y-16.84%
OCF growth 5Y63.58%

THYSSENKRUPP NUCERA AG & CO / NCH2.DE FAQ

What is the fundamental rating for NCH2 stock?

ChartMill assigns a fundamental rating of 3 / 10 to NCH2.DE.


What is the valuation status for NCH2 stock?

ChartMill assigns a valuation rating of 1 / 10 to THYSSENKRUPP NUCERA AG & CO (NCH2.DE). This can be considered as Overvalued.


What is the profitability of NCH2 stock?

THYSSENKRUPP NUCERA AG & CO (NCH2.DE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for THYSSENKRUPP NUCERA AG & CO?

The Earnings per Share (EPS) of THYSSENKRUPP NUCERA AG & CO (NCH2.DE) is expected to decline by -38.12% in the next year.